This site is intended for healthcare professionals

NICE recommends Rinvoq to treat severe Rheumatoid Arthritis.- AbbVie

Read time: 1 mins
Published:3rd Feb 2020
The National Institute for Health and Care Excellence (NICE) has recommended Rinvoq (upadacitinib) from AbbVie together with standard-of-care methotrexate, for coverage on the National Health Service as a treatment for severe rheumatoid arthritis, according to draft guidance. Rinvoq, with a list price of £805.56 ($1,058.06) per 28-day pack and average annual cost per patient of £10,508 ($13,801), will come with a confidential discount. Despite the success in severe RA, NICE did not accept Rinvoq's application to treat moderate RA, stating that the drug's price didn't meet its cost-effectiveness standard in that indication.
Condition: Rheumatoid Arthritis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.